Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EASYTRAK 3 left ventricular pacing lead · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| EASYTRAK 3 left ventricular pacing lead | DEVICE | - |
Inclusion Criteria: * Moderate to severe heart failure (NYHA Class III/IV) including left ventricular dysfunction (EF \<= 35%) and QRS duration \>= 120 ms remaining symptomatic despite stable, optimal heart failure drug therapy. * Creatinine \< 2.5 mg/dL obtained no more than two weeks prior to enr...
The EASYTRAK 3 left ventricular pacing lead is used for congestive heart failure. It is an investigational device being studied for this condition. The lead is designed for placement in the coronary venous system to deliver pacing to the left ventricle.
Boston Scientific Corporation (BSX) develops the EASYTRAK 3 left ventricular pacing lead. The company is conducting clinical research on this device for congestive heart failure.
The EASYTRAK 3 left ventricular pacing lead is in Phase 2 clinical development. It is an investigational device and has not been approved by the FDA. One Phase 2 study has been completed.
The EASYTRAK 3 left ventricular pacing lead was studied in clinical trial NCT00158938, titled 'Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense Lead'. This Phase 2 study enrolled 115 participants with congestive heart failure and has been completed.
Yes, EASYTRAK 3 left ventricular pacing lead is the same as EASYTRAK 3. The full name includes the description 'left ventricular pacing lead', while the clinical trial refers to it as the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense Lead.